Based on quality, trust and flexibility we work as a natural extension of your own team.
Why Choose SQN
We have the necessary knowledge and experience to support your planned clinical studies no matter how simple or complex the study design or therapeutic focus will be. With a global reputation for service excellence, delivering high quality, on time and within agreed budgets, we can be trusted to meet all your commercial and clinical development needs.
Simply put, we keep our promises.
SQN – the biometrics partner of choice for so many clinical development professionals like you
Our Services
ePRO & patient centric data
Driving patient centricity, innovating patient reported outcomes
Many thanks for delivering this project to time; it has been an intense journey, made pleasant by SQN’s professional and knowledgeable staff. Please send my sincere thanks and gratitude to the team. All of the staff at SQN have done a great job in guiding us smoothly to a successful outcome [ISE/ISS submission] and have delivered as promised.
GLOBAL PHARMA
I have been very impressed with the way you guys have managed this study and grateful to have had you on the team. Well done to you all and thank you for all your hard work.
BIOTECH
I’ve never seen our research nurses so enthusiastic about an EDC System
PRINCIPAL INVESTIGATOR
This was my first audit of this type. It is quite rare for me to give spontaneous feedback, but it is deserved. It was very easy and even pleasant. Your auditor was very professional, motivated and gave us a wonderful impression – so helpful and kind that we did not want to switch off our skype session.
PHARMA
In the News and from our Blog
04 02 2020
Introduction There’s often a reticence around adopting electronic solutions for traditional processes – EDC took hold across the industry, but it was a long slow introduction. ePRO is starting to take off now too, but...
04 12 2019
You will undoubtedly have already engaged with the relevant authorities and had those concept discussions throughout your development and late phase studies. Now with confidence high and the pivotal studies coming to a close it...